Skip to main content

Table 1 Characteristics of type 2 diabetes population according to cardiovascular risk

From: Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study

 

Moderate risk

High risk

Very high risk

p

Number of subjects

2,819

98,781

372,140

 

Age (years)

41.6 ± 6.8

66.7 ± 13.1

70.0 ± 10.2

 < 0.0001

Sex (% male)

57.6

56.5

57.2

0.0003

New diagnoses (%)

25.3

9.9

4.9

 < 0.0001

Diabetes duration (years)

3.0 ± 2.8

10.1 ± 8.9

12.9 ± 9.5

 < 0.0001

BMI (kg/m2)

25.6 ± 2.8

27.0 ± 4.5

30.0 ± 5.5

 < 0.0001

Smokers (%)

0.0

7.6

19.2

 < 0.0001

HbA1c (%)

7.3 ± 1.7

7.1 ± 1.3

7.2 ± 1.2

0.002

Blood pressure (mmHg)

 Systolic

116.4 ± 11.2

130.1 ± 17.0

136.5 ± 18.3

 < 0.0001

 Dyastolic

73.3 ± 7.7

75.9 ± 9.2

76.9 ± 9.7

 < 0.0001

Total Cholesterol (mg/dl)

175.1 ± 31.2

174.0 ± 33.9

167.1 ± 38.8

 < 0.0001

LDL Cholesterol (mg/dl)

97.8 ± 20.6

97.2 ± 27.8

91.0 ± 32.7

 < 0.0001

HDL Cholesterol(mg/dl)

48.5 ± 13.2

51.1 ± 13.7

48.1 ± 12.7

 < 0.0001

Triglicerides (mg/dl)

135.8 ± 106.0

125.8 ± 78.1

141.1 ± 81.6

 < 0.0001

Albuminuria (%)

0.0

0.0

39.5

 < 0.0001

eGFR < 30 ml/min/1,73m2 (%)

0.0

0.0

8.8

 < 0.0001

Anti-hyperglycemic therapy (%)

 Metformin

72.0

71.1

69.0

 < 0.0001

 DPP4-i

13.3

19.8

21.5

 < 0.0001

 Secretagogues

7.7

15.9

16.3

 < 0.0001

 Glinides

1.2

3.6

3.7

 < 0.0001

 SGLT2-i

8.5

7.7

10.0

 < 0.0001

 Glitazones

3.1

4.0

4.4

 < 0.0001

 Acarbose

1.1

2.0

2.5

 < 0.0001

 GLP1-RA

2.4

3.9

6.4

 < 0.0001

 Insulin

27.6

24.4

34.5

 < 0.0001

Diabetes treatment scheme (%)

 Oral Monotherapy

38.1

35.7

27.4

 < 0.0001

 Oral Two fold therapy

19.2

23.0

21.7

 < 0.0001

 Three or more oral drugs

3.3

6.0

6.5

 < 0.0001

 GLP1-RA ± other drugs

2.4

3.9

6.4

 < 0.0001

 Insulin + oral drugs

12.8

12.8

19.1

 < 0.0001

 Multiple daily insulin injections

14.5

10.9

14.2

 < 0.0001

 Anti-hypertensive therapy (%)

0.0

32.9

80.4

 < 0.0001

 Lipid-lowering therapy (%)

0.0

18.0

72.6

 < 0.0001

 Retinopathy (%)

0.0

0.0

26.4

 < 0.0001

  Non proliferative

0.0

0.0

19.5

 

  Pre-proliferative

0.0

0.0

1.9

 

  Proliferative

0.0

0.0

1.8

 

  Laser-treated

0.0

0.0

2.6

 

  Oftalmopathy

0.0

0.0

0.2

 

  Blindness

0.0

0.0

0.3

 

Previous myocardial infarction (%)

0.0

0.0

9.5

 < 0.0001

Previous stroke (%)

0.0

0.0

3.3

 < 0.0001

Established cardiovascular disease (%)

0.0

0.0

18.7

 < 0.0001

Dialisys (%)

0.0

0.0

0.3

 < 0.0001